Achieve Life Sciences, Inc. (NASDAQ:ACHV) Given Consensus Recommendation of “Buy” by Brokerages

Shares of Achieve Life Sciences, Inc. (NASDAQ:ACHVGet Free Report) have been assigned an average recommendation of “Buy” from the six brokerages that are currently covering the firm, MarketBeat.com reports. Four research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. The average 1-year target price among brokers that have covered the stock in the last year is $14.80.

ACHV has been the subject of a number of research analyst reports. Raymond James assumed coverage on shares of Achieve Life Sciences in a research note on Friday, September 27th. They issued a “strong-buy” rating and a $20.00 target price for the company. Rodman & Renshaw assumed coverage on shares of Achieve Life Sciences in a research report on Thursday, November 14th. They issued a “buy” rating and a $12.00 price objective for the company. Finally, RODMAN&RENSHAW upgraded Achieve Life Sciences to a “strong-buy” rating in a research report on Thursday, November 14th.

Check Out Our Latest Report on ACHV

Achieve Life Sciences Stock Performance

NASDAQ:ACHV opened at $3.38 on Friday. The stock has a market capitalization of $116.24 million, a P/E ratio of -2.99 and a beta of 1.66. The company has a current ratio of 6.78, a quick ratio of 6.78 and a debt-to-equity ratio of 0.31. Achieve Life Sciences has a 1 year low of $3.37 and a 1 year high of $5.59. The firm has a 50 day moving average of $4.20 and a 200-day moving average of $4.50.

Achieve Life Sciences (NASDAQ:ACHVGet Free Report) last announced its earnings results on Thursday, November 7th. The biopharmaceutical company reported ($0.36) EPS for the quarter, missing the consensus estimate of ($0.26) by ($0.10). During the same period in the prior year, the company posted ($0.34) earnings per share. As a group, sell-side analysts anticipate that Achieve Life Sciences will post -1.17 EPS for the current fiscal year.

Institutional Trading of Achieve Life Sciences

Hedge funds have recently added to or reduced their stakes in the business. SG Americas Securities LLC bought a new stake in Achieve Life Sciences in the 3rd quarter valued at approximately $54,000. The Manufacturers Life Insurance Company acquired a new stake in Achieve Life Sciences in the 2nd quarter valued at about $69,000. MetLife Investment Management LLC boosted its stake in shares of Achieve Life Sciences by 65.6% during the 3rd quarter. MetLife Investment Management LLC now owns 14,993 shares of the biopharmaceutical company’s stock worth $71,000 after acquiring an additional 5,939 shares during the period. Verition Fund Management LLC bought a new position in Achieve Life Sciences during the third quarter worth $113,000. Finally, Renaissance Technologies LLC grew its stake in Achieve Life Sciences by 134.2% in the 2nd quarter. Renaissance Technologies LLC now owns 25,060 shares of the biopharmaceutical company’s stock valued at $118,000 after buying an additional 14,360 shares during the last quarter. Institutional investors and hedge funds own 33.52% of the company’s stock.

About Achieve Life Sciences

(Get Free Report

Achieve Life Sciences, Inc, a clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms.

Featured Articles

Analyst Recommendations for Achieve Life Sciences (NASDAQ:ACHV)

Receive News & Ratings for Achieve Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achieve Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.